Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006229 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 study, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 774
- Enrollment target
NCT00006229: Completed Phase 2 study, sponsored by NCIC Clinical Trials Group.
NCT00006229 is a Phase 2 study that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 774 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (482% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006229, a Phase 2 study, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 774 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel and carboplatin are more effective with or without BMS-275291 for non-small cell lung cancer. PURPOSE: Randomized phase II/III trial to compare the effectiveness of paclitaxel and carboplatin with or without BMS-275291 in treating patients who have advanced or metastatic non-small cell lung cancer.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- DRUG rebimastat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 774 participants |
| Start Date | 2000-04-04 |
| Est. Completion | 2009-02-10 |
| Phase | Phase 2 |
What the finished NCT00006229 record still lists
NCT00006229 is an interventional study that assigns participants to a tested intervention. The registered 774 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (482% higher).
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00006229 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006229 about?
NCT00006229 is a clinical study titled "Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel and carboplatin are more effective with or without BMS-275291 for non-small cell lung cancer. PURPOSE: Randomized phase II/III trial to comp...
What is the current status of trial NCT00006229?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 774 participants. The study started on 2000-04-04. Estimated completion is 2009-02-10.
What interventions are being tested in trial NCT00006229?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), rebimastat (DRUG).
Who is sponsoring clinical trial NCT00006229?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00006229's enrollment target sits among peer trials
774 42nd of 2000 higher than 1,959 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03460769 · 775 participants
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
- NCT06145763 · 776 participants · NA
A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial
- NCT05642611 · 777 participants · Phase 3
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
- NCT06841679 · 778 participants · Phase 2
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI